Fu Wai Hospital, Beijing, China is the lead sponsor of 6 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Aspirin, Colchicine and GDMT. The most-studied condition is Heart Failure.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
NCT06090890 · ClinicalTrials.gov ↗ · In-stent Restenosis
|
Phase 4 | Recruiting | 2023-10 | China |
|
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
NCT04240834 · ClinicalTrials.gov ↗ · Acute Coronary Syndrome, Interventional Cardiology
Drugs: Aspirin, Ticagrelor |
Phase 4 | Recruiting | 2021-02 | China |
|
Risk Prediction of Disease Progression in Early-Onset Coronary Atherosclerosis
NCT07316452 · ClinicalTrials.gov ↗ · Coronary Disease, Young Adult
|
Observational | Recruiting | 2025-01 | China |
|
Stepwise vs Standard Anticoagulation for AF Patients Undergoing CIED Implantation (STEP-AF)
NCT07616414 · ClinicalTrials.gov ↗ · Non-valvular Atrial Fibrillation (NVAF), Thromboembolism, Cardiac Implantable Electronic Device
|
Not applicable | Not yet open | 2026-05 | China |
|
Bachmann Bundle Pacing for Prevention of New-Onset Atrial Fibrillation in Patients With Heart Failure
NCT07547449 · ClinicalTrials.gov ↗ · Heart Failure, Atrial Fibrillation (AF), Cardiac Insufficiency
|
Not applicable | Not yet open | 2026-04 | China |
|
Clinical Efficacy of Early Left Bundle Branch Pacing for Cardiac Resynchronization Therapy
NCT06126081 · ClinicalTrials.gov ↗ · Heart Failure, Left Bundle Branch Pacing
Drug: GDMT |
Not applicable | Active, closed | 2023-06 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 6 | 3 |
A trial with sites in more than one country appears in each of those registers.
Sponsors with the most current trials registered for this condition.
Fu Wai Hospital, Beijing, China is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 5 drugs and biologicals as interventions. The most frequent are Aspirin (2), Colchicine (1), GDMT (1), Prednisone (1) and Ticagrelor (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.